How much does a fake Turkey passport cost?【visit: hk965.com】【whatsapp:+852 92908202】【telegram:hz99888】Professional production of documents, including passports, visas, driver's licenses, ID cards, green cards, residence cards, various certificates, and utility bills Global shipping, safe and fast. Contact us if needed.,【Customized website: https://hk965.com】,【whatsapp:+852 92908202】【telegram:@hz99888】How much does a fake Turkey passport cost?,How much does a fake Turkey passport cost?. . . . . . . . The rapid development of the parkis the result of the continuous struggle of generations of people in the parkIt also embodies the power of each enterprise to take root and growIn the parkOne batch of enterprises after anotherrelying on their "hard skills" to become "top""Raising the Line"wrotea wonderful chapter of "Thirty Years of Striving, Building Dreams for the Future"Displaying in all aspectsThe high-spirited attitude of the park enterprisesThe park released a series of reports"Continue to Struggle""Building Dreams with Enterprises"BelowLet's take a look at the second articleBeiGeneBased on Suzhou and serving the worldLet innovative drugs benefit more patientsOn Xinze Road in Suzhou Industrial Park, BeiGene's new small molecule innovative drug industrialization base is "operating" at high speed.The base was put into use at the end of last year. It has both commercial-scale production capabilities and flexible production capabilities for clinical drugs. It can quickly realize high-quality transformation from laboratory to clinical product production and then to commercial production. It is expected that the annual output of solid preparations can reach up to 1 billion tablets/grain.This has also become an important milestone in the development of BeiGene.BeiGene (Suzhou) Biotechnology Co., Ltd.Founded in 2015, it is one of the 鈥渓eaders鈥?in the park鈥檚 biopharmaceutical companies.The company is based in Suzhou and looks at the world, focusing on developing innovative anti-tumor drugs for cancer patients around the world.Over the years, BeiGene has been deeply involved in the park and innovative development. Through its strong independent research and development capabilities and external strategic cooperation, it has continuously accelerated the development of diversified and innovative drug pipelines and product portfolios, and continued to improve the accessibility and affordability of drugs.The company has been rated as a national high-tech enterprise and has qualifications such as Jiangsu Provincial Engineering Technology Research Center, Specialized and New "Little Giant" Enterprise, and Jiangsu Provincial Enterprise Technology Center.Deeply exploring the "track" of innovative drugsA number of products have been approved for marketingSince the establishment of the companyBeiGene has been deeply involved in research and developmentIn the two major fields of small molecule innovative drugs and large molecule drugsAccelerate effortsActively promote multipleResearch and development of innovative drugsRealized in the parkClinical and commercial scale production of multiple small molecule drugsSo far, BeiGene has independently developed three drugs that have been approved for marketing - including the innovative small molecule drugs Byzantine?Currently, Baiyueze? has been approved for marketing in 70 countries and regions including the United States, China, the European Union, the United Kingdom, Canada, and Australia, and Baizean? has been approved for marketing in China, the European Union, and the United States.From "birth" to "marketing", an innovative drug often undergoes a long cycle of R&D, production and commercialization.BeiGene focuses on the entire process of innovative drug R&D and production, promotes the construction of BeiGene Suzhou Pharmaceutical R&D Center, builds an innovative drug industrialization park, and builds an internal global clinical team to promote the "seamless connection" of clinical, R&D, and production.To date, BeiGene has independently conducted more than 130 clinical trials and enrolled more than 22,000 subjects in approximately 45 countries and regions.鈥淪tarting from the Suzhou base, BeiGene has built important technical operations and independent production capabilities globally, and is committed to creating a diversified global supply layout.鈥?Lu Liqiang, vice president of BeiGene and general manager of Suzhou, said that currently, BeiGene has built production bases in Suzhou, Guangzhou, China, and Hopewell, New Jersey, the United States, to meet the global commercialization and clinical trial supply needs of drugs, and promote the company to quickly improve the world鈥檚 most differentiated full industry value chain.Growing in the fertile ground for innovationBuilding an innovative drug industrialization parkBiomedicine is a strategic emerging industry that the park focuses on supporting.Over the years, the park has taken a multi-pronged approach in terms of policies, funds, talents, and resources to create a fertile ground for innovation and build a sound ecosystem for biopharmaceutical companies to thrive.In the past ten years of mutual companionship and common growth, BeiGene has witnessed the rapid development of the park, and the park has also done its best to support every step of the company's growth."Over the years, the park has witnessed many key nodes in the development of BeiGene, including the commercial production and supply of two independently developed products - Baiyue Ze? and Baiji Ze?, as well as the construction of a new base in Suzhou, etc. At these important development nodes, the park has always given the company the greatest support and help. It is relying on the park's policy support, talent introduction, technology transfer and other services that the company can grow steadily and achieve remarkable results in the industry." Lu Liqiang said.Innovative pharmaceutical companiesIf they want to transform R&D results intocommercialized products that truly help patients they must cross an important hurdle of industrializationThis is also a concrete manifestation of the company鈥檚 strengthAfter years of development and accumulation, BeiGene鈥檚 Suzhou base has grown into a mature innovative drug industrialization park.Among them, the BioBAY factory located on Sangtian Island is a production base for clinical drug candidates and small molecule commercial drugs. It is expected to produce 100 million solid preparations per year and has a production capacity of 2脳500 liters of biological clinical development products.The first phase of the new small molecule innovative drug industrialization base has added more than 52,000 square meters, which can provide strong production support for small molecule commercial drugs and clinical candidate drugs in the continuously growing product pipeline. It is currently one of the few integrated bases in the world that can realize the industrialization of new drugs.It is worth mentioning that in September last year, BeiGene鈥檚 Suzhou base successfully passed the cGMP (Current Good Manufacturing Practice) on-site inspection of the U.S. Food and Drug Administration (FDA), marking that Baiyueze produced at the Suzhou base has officially obtained the qualification to commercially supply the U.S. market.This also proves that the quality system of BeiGene's Suzhou base has reached internationally recognized high standards and high maturity, laying a solid foundation for better serving patients around the world and providing high-quality, high-efficiency, affordable innovative drugs.Be a "leader" in the industryPromote the innovation and development of the biopharmaceutical industryIn recent yearsBeiGene has continued to grow and received frequent good newsAs the first small molecule innovative drug created by the company, Baiyize? was approved for marketing in the United States in 2019, achieving a "zero breakthrough" for innovative drugs to go overseas.This marks that Baiyueze? has become the first new anti-cancer drug in the history of Chinese pharmaceuticals that was completely independently developed by a company and approved by the FDA.鈥淭he park鈥檚 complete industrial ecology and superior business environment provide comprehensive and strong support for the sustainable and high-quality development of enterprises. Looking forward to the future, BeiGene will continue to take root in Suzhou and the park, and strengthen its confidence and determination to deepen the research and development of innovative drugs.鈥?Lu Liqiang said that BeiGene will continue to strengthenAdhering to the development concept of patients first and science-based, we actively work with all parties to jointly promote the industrial development and innovation upgrade of innovative drugs; at the same time, we continue to strengthen cooperation and exchanges with other companies in the industry and the park to better bring accessible and affordable innovative drugs to patients around the world, and help promote better development of the biopharmaceutical industry.